Abstract
THE EUROPEAN ACADEMY OF TUMOR IMMUNOLOGY (EATI, OFFICIAL WEBSITE: http://eati.landesbioscience.com/index.html) has been founded in 2011 with the idea of creating a novel organization that responds to the need of structuring the European research space in this expanding, clinically ever more important area of research. Rapidly, this initiative, which regroups (part of) the elite of tumor immunologists, has been joined by 110 scientists, who accepted to join EATI as founding members. Obviously, EATI will not enter in competition with existing prestigious organizations, be they supranational (such as the Cancer Research Institute, CRI; the European Society for Cancer Immunology and Immunotherapy, ESCII; and the Society for the Immunotherapy of Cancer, SITC), or national [such as the Cancer Immunology Working Group, CIMM, of the American Association for Cancer Reserch; the (German) Association for Cancer Immunotherapy, CIMT; the (US) Cancer Immunotherapy Consortium, CIC; the (US) Cancer Vaccine Consortium, CVC; and the Italian Network for Cancer Biotherapy, NIBIT]. The choice of cooperation (rather than competition) with these organizations is clearly documented by the fact that many prominent members of CIMM, CIC, CIMT, CRI, CVC, ESCII, NIBIT and SITC are also EATI Academicians.